for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allena Pharmaceuticals Inc

ALNA.O

Latest Trade

1.42USD

Change

0.00(0.00%)

Volume

37,327

Today's Range

--

 - 

--

52 Week Range

0.52

 - 

6.30

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Empery Asset Management Lp Reports 8.71% Passive Stake In Allena Pharmaceuticals As Of June 3

* EMPERY ASSET MANAGEMENT LP REPORTS 8.71% PASSIVE STAKE IN ALLENA PHARMACEUTICALS AS OF JUNE 3 - SEC FILING Source text - https://bit.ly/2ARAr0b Further company coverage:

BRIEF-Allena Pharmaceuticals Announces $15.0 Mln Registered Direct Offering

* ALLENA PHARMACEUTICALS ANNOUNCES $15.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share Of $0.31

* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharmaceuticals Reports Q4 Loss Per Share Of $0.47

* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER 2019 AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharma Announces Streamlined Design For Urirox-2, Second Pivotal Clinical Trial Of Reloxaliase For Enteric Hyperoxaluria

* ALLENA PHARMACEUTICALS ANNOUNCES STREAMLINED DESIGN FOR URIROX-2, SECOND PIVOTAL CLINICAL TRIAL OF RELOXALIASE FOR ENTERIC HYPEROXALURIA

BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38

* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharmaceuticals Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $0.48

* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria

* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA

BRIEF-HBM BioCapital II reports 7.94 pct passive stake in Allena Pharma

* HBM BioCapital II LP reports 7.94 percent passive stake in Allena Pharmaceuticals Inc as of November 6, 2017 - SEC filing Source text: (http://bit.ly/2A4iWbx) Further company coverage:

BRIEF-Allena Pharmaceuticals shares open 14.3 pct below IPO price in debut

* Allena Pharmaceuticals shares open at $12 in debut on the NASDAQ versus IPO price of $14/shr Further company coverage:

IFR Americas ECM Pipeline

Allena Pharmaceuticals (US, biotech) – $74.6m IPO. 5.33m shares (100% prim) at $14.00 versus $14-$16 marketing. CS, JEFF, COWN. Algonquin Power & Utilities (Canada, utility) – C$500m Block. 37.8m shares (100% prim) at C$13.25 versus C$13.75 last sale. SCOT, CIBC, TD. Assembly...

BRIEF-Allena Pharmaceuticals prices IPO of 5.3 mln shares at $14 per share

* Allena pharmaceuticals, Inc. Announces pricing of initial public offering

BRIEF-Allena Pharmaceuticals sees IPO price range of $14-$16/shr

* Allena pharmaceuticals Inc sees IPO of up to 5.33 million shares of common stock to be priced between $14 and $16 per share - SEC filing Source text: [http://bit.ly/2zvbZf3] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up